# A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

> **NCT05929079** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 1000 (estimated)

## Conditions studied

- Type 2 Diabetes
- Obesity
- Overweight
- Obstructive Sleep Apnea

## Interventions

- **DRUG:** Retatrutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05929079
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-11
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05929079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05929079, "A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05929079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*